GlassScriptPhysician profile
Ahmad Babar
NPI 1144665407
$4,820.78
in general payments reported to CMS, 2019-2025
29 companies · $1,265 in 2025
The $1,265 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $91.35 · 2021: $467 · 2022: $744 · 2023: $857 · 2024: $1,396 · 2025: $1,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,490 · Education: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,490.17 |
| Education | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,187.49 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $814.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $520.91 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Insulet Corporation | $332.00 | 2024-2025 | Omnipod |
| Pfizer INC. | $278.43 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $257.31 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $197.28 | 2021-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $161.17 | 2022-2025 | |
| Glaxosmithkline, LLC. | $108.49 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Currax Pharmaceuticals LLC | $103.51 | 2022-2024 | Contrave, Nexlizet, Nexletol |
| Exact Sciences Corporation | $96.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.42 | 2021-2025 | Jardiance |
| Amgen INC. | $90.58 | 2020-2025 | Evenity, Prolia, Prolia |
| Alk-Abello, INC | $74.62 | 2024-2025 | Grastek, Ragwitek, Odactra |
| Mylan Specialty L.P. | $70.19 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.37 | 2024 | Xifaxan, Trulance |
| Philips North America LLC | $52.09 | 2023 | |
| Janssen Pharmaceuticals, INC | $47.07 | 2022 | |
| Vanda Pharmaceuticals INC. | $45.75 | 2022 | |
| Abbvie INC. | $35.27 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $34.26 | 2021-2022 | |
| Atricure, INC. | $28.54 | 2022 | |
| Amarin Pharma, INC. | $22.96 | 2022 | |
| Organon LLC | $22.67 | 2022 | |
| Coopersurgical, INC. | $18.81 | 2022 | |
| Medtronic, INC. | $17.60 | 2025 | Inceptiv |
| Genentech USA, INC. | $17.51 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.78 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.93 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Babar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.